RZL-12 is under clinical development by Raziel Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect RZL-12’s likelihood of approval (LoA) and phase transition for Adiposis Dolorosa (Dercum’s Disease or Anders Disease) took place on 25 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
In addition, the same event on 25 Apr 2022 increased RZL-12’s LoA and PTSR for Obesity.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their RZL-12 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
RZL-12 is under development for the treatment of obesity, submental fat reduction, lipedema involving substantial fat above the knee and nodular Dercum's disease. The drug candidate is a new chemical entity administered through subcutaneous route.
Raziel Therapeutics overview
Raziel Therapeutics, a clinical-stage pharmaceutical company that developing RZL-012, an injectable treatment for aesthetics and a variety of fat disorders. The company is headquartered in Israel.
Quick View RZL-12 LOA Data
|Highest Development Stage|